A recent study investigated the levels of specific DNA fragments in the blood of ovarian cancer patients. The findings could eventually lead to a blood test that can make accurate predictions about tumor size and disease progression.
Ovarian cancer affects around 20,000 women in the United States each year. It is the ninth most common cancer in the U.S., but the fifth leading cause of cancer death.
The earlier ovarian cancer is caught, the more likely treatment is to be successful.
Currently, as with most other cancers, assessing how well a treatment is performing is difficult. In a perfect world, if doctors had full visibility of how a tumor was responding to a certain medication, they would be able to manipulate the drug type and schedule with more confidence.